Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

4,652 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A randomized, double-blind, placebo-controlled phase 1b/2 study of ralimetinib, a p38 MAPK inhibitor, plus gemcitabine and carboplatin versus gemcitabine and carboplatin for women with recurrent platinum-sensitive ovarian cancer.
Vergote I, Heitz F, Buderath P, Powell M, Sehouli J, Lee CM, Hamilton A, Fiorica J, Moore KN, Teneriello M, Golden L, Zhang W, Pitou C, Bell R, Campbell R, Farrington DL, Bell-McGuinn K, Wenham RM. Vergote I, et al. Among authors: campbell r. Gynecol Oncol. 2020 Jan;156(1):23-31. doi: 10.1016/j.ygyno.2019.11.006. Epub 2019 Nov 29. Gynecol Oncol. 2020. PMID: 31791552 Clinical Trial.
A phase 1 dose-escalation study of checkpoint kinase 1 (CHK1) inhibitor prexasertib in combination with p38 mitogen-activated protein kinase (p38 MAPK) inhibitor ralimetinib in patients with advanced or metastatic cancer.
Bendell JC, Bischoff HG, Hwang J, Reinhardt HC, Zander T, Wang X, Hynes S, Pitou C, Campbell R, Iversen P, Farrington DL, Bell-McGuinn K, Thomas M. Bendell JC, et al. Among authors: campbell r. Invest New Drugs. 2020 Aug;38(4):1145-1155. doi: 10.1007/s10637-019-00873-6. Epub 2019 Nov 9. Invest New Drugs. 2020. PMID: 31707688 Clinical Trial.
A multicenter retrospective comparison of induction chemoimmunotherapy regimens on outcomes in transplant-eligible patients with previously untreated mantle cell lymphoma.
Ng ZY, Bishton M, Ritchie D, Campbell R, Gilbertson M, Hill K, Ratnasingam S, Schwarer A, Manos K, Shorten S, Ng M, Nelson N, Xin L, De Mel Widanalage S, Sunny T, Purtill D, Poon M, Johnston A, Cochrane T, Lee HP, Hapgood G, Tam C, Opat S, Hawkes E, Seymour J, Cheah CY. Ng ZY, et al. Among authors: campbell r. Hematol Oncol. 2019 Aug;37(3):253-260. doi: 10.1002/hon.2618. Epub 2019 May 24. Hematol Oncol. 2019. PMID: 30983008
Pharmacogenetic-guided dosing for fluoropyrimidine (DPYD) and irinotecan (UGT1A1*28) chemotherapies for patients with cancer (PACIFIC-PGx): A multicenter clinical trial.
Glewis S, Lingaratnam S, Lee B, Campbell I, IJzerman M, Fagery M, Harris S, Georgiou C, Underhill C, Warren M, Campbell R, Jayawardana M, Silva SSM, Martin JH, Tie J, Alexander M, Michael M. Glewis S, et al. Among authors: campbell i, campbell r. Clin Transl Sci. 2024 Dec;17(12):e70083. doi: 10.1111/cts.70083. Clin Transl Sci. 2024. PMID: 39614408 Free PMC article. Clinical Trial.
Outcomes of stage I/II follicular lymphoma in the PET era: an international study from the Australian Lymphoma Alliance.
Tobin JWD, Rule G, Colvin K, Calvente L, Hodgson D, Bell S, Dunduru C, Gallo J, Tsang ES, Tan X, Wong J, Pearce J, Campbell R, Tneh S, Shorten S, Ng M, Cochrane T, Tam CS, Abro E, Hawkes E, Hodges G, Kansara R, Talaulikar D, Gilbertson M, Johnston AM, Savage KJ, Villa D, Morris K, Ratnasingam S, Janowski W, Kridel R, Cheah CY, MacManus M, Matigian N, Mollee P, Gandhi MK, Hapgood G. Tobin JWD, et al. Among authors: campbell r. Blood Adv. 2019 Oct 8;3(19):2804-2811. doi: 10.1182/bloodadvances.2019000458. Blood Adv. 2019. PMID: 31570492 Free PMC article.
Pharmacogenomics guided dosing for fluoropyrimidine and irinotecan chemotherapies for patients with cancer (PACIFIC-PGx): study protocol of a multicentre clinical trial.
Glewis S, Alexander M, Lingaratnam S, Lee B, Campbell I, Krishnasamy M, IJzerman M, Fagery M, Harris S, Georgiou C, Underhill C, Warren M, Campbell R, Martin J, Tie J, Michael M. Glewis S, et al. Among authors: campbell i, campbell r. Acta Oncol. 2022 Sep;61(9):1136-1139. doi: 10.1080/0284186X.2022.2109423. Epub 2022 Aug 16. Acta Oncol. 2022. PMID: 35972781 No abstract available.
Patient and healthcare professional acceptability of pharmacogenetic screening for DPYD and UGT1A1: A cross sectional survey.
Glewis S, Krishnasamy M, Lingaratnam S, Harris S, Underhill C, Georgiou C, Warren M, Campbell R, IJzerman M, Fagery M, Campbell I, Martin JH, Tie J, Alexander M, Michael M. Glewis S, et al. Among authors: campbell i, campbell r. Clin Transl Sci. 2023 Dec;16(12):2700-2708. doi: 10.1111/cts.13664. Epub 2023 Oct 31. Clin Transl Sci. 2023. PMID: 37877594 Free PMC article.
Definition of sinonasal and otological exacerbation in patients with primary ciliary dyskinesia: an expert consensus.
Goutaki M, Lam YT, Anagiotos A, Armengot M, Burgess A, Campbell R, Carlier M, Caversaccio N, Chadha NK, Demir B, Dheyauldeen SAD, Gunaydin O, Harris A, Hayn I, Inal-Ince D, Levi E, Fernandez TL, Lucas JS, Maitre B, Poirrier AML, Schofield L, Takeuchi K, van Gogh C, Wolter NE, Papon JF. Goutaki M, et al. Among authors: campbell r. ERJ Open Res. 2024 Dec 16;10(6):00218-2024. doi: 10.1183/23120541.00218-2024. eCollection 2024 Nov. ERJ Open Res. 2024. PMID: 39698064 Free PMC article.
4,652 results